[The use of the new cardioprotective agent thiotriazoline in the therapy of ischemic heart disease in older patients].
The effect of tiotriazolin on the efficiency of antianginal therapy in aged patients with cardiac disease CD is studied. Clinical tests, functional (ECG, electrocardiotopography, cardiohemodynamics, etc.) and biochemical (indices of lipid peroxidation activity) methods of control were used as criteria of the treatment efficiency. Tiotriazolin was found to increase significantly the efficiency of basic drugs for CD treatment in aged patients.